| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 2 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
Lerdelimumab (CAT-152, intended trade nameTrabio) is ahumanmonoclonal antibody and animmunosuppressive drug targetingTGF beta 2.
It was being developed to reduce scarring afterglaucoma drainage surgery.[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.[2]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
